Teriparatide Induced Delayed Persistent Hypercalcemia

الملخص EN

Teriparatide, a recombinant PTH, is an anabolic treatment for osteoporosis that increases bone density.

Transient hypercalcemia is a reported side effect of teriparatide that is seen few hours following administration of teriparatide and resolves usually within 16 hours of drug administration.

Persistent hypercalcemia, although not observed in clinical trials, is rarely reported.

The current case describes a rare complication of teriparatide induced delayed persistent hypercalcemia.